MaxCyte Reports Preliminary Q3 2026 Revenue and Raises FY 2026 Revenue Guidance

MaxCyte, Inc., (NASDAQ: MXCT ), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced preliminary revenue for the third quarter ended September 30, 2026 and raised its 2026 revenue guidance. Core business revenue of approximately $8.1 million in the third quarter of 2026, an increase of 26% compared to the third quarter of 2025. Full Year 2026 Guidance MaxCyte raises 2026 revenue guidance for core business revenue and SPL Program-related revenue: Full year revenue expected to be approximately $34 million, compared to prior guidance of $30 million to $32 million, consisting of: Core business revenue of approximately $28 million, compared to prior guidance of $25 million to $27 million. SPL Program-related revenue of approximately $6 million for the year, compared to prior guidance of approximately $5 million; SPL Program-related revenue guidance includes both revenue of approximately $4 million from milestone payments and approximately $2 million from commercial royalties.

MaxCyte reported preliminary third-quarter 2026 revenue driven by approximately $8.1 million of core business revenue and more than $1.0 million of Strategic Platform License (SPL) Program-related revenue, including a $1.0 million milestone. The company raised full-year 2026 revenue guidance to app…